Researchers at Duke University have utilized autologous (the patient’s own) stem cell infusions to promote increased connectivity in the brain that allowed for improved communication and language abilities in children with Autism Spectrum Disorder (ASD). The stem cells used in the trial were the patients’ own cord blood stem cells, which were banked at birth and played a key role in alleviating the symptoms of ASD in these patients.
Widecells Group PLC (LON:WDC) are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.